We present the case of a 72-year-old Caucasian woman with frontal fibrosing alopecia of one year's duration. Eighteen months later, she presented with sudden hyperpigmentation on the submental area, neck and upper chest. Histopathological examination was consistent with lichen planus pigmentosus. This is the report of a unique case of a FFA and extrafacial lichen planus pigmentosus.
INTRODUCTION
Frontal fibrosing alopecia (FFA) is a lymphocytic cicatricial alopecia that shares common histophalologic features with lichen planopilaris. FFA can be associated with cutaneous or mucosal lichen planus, and recently with lichen planus pigmentosum (LPP).
This association was first reported by Dlova in 2013 in south African patients. 1 Most cases are women, with dark skin and LPP with facial involvement. 
CASE REPORT
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FIgure 1: Alopecia over the frontotemporal region and loss of eyebrow Clinically, lesions appear as small, ill-defined oval to round macules, which may be discrete or become confluent to form large patches. The pigmentation varies from slate gray to dark brown.
It primarily affects sun-exposed areas. The differential diagnosis of LPP should be established with a group of hyperpigmentation disorders, such as melasma, exogenous ochronosis, Riehl's melanosis and erythema dyschromicum perstans (EDP) or ashy dermatosis. LPP and EDP share many clinical and histopathologic similarities. 5 EDP usually affects the trunk and upper extremities and presents melanin deposits mainly in deeper dermis, unlike LPP, which is located in the superficial dermis. Pigmentation from antimalarial is another differential diagnosis because it is a common treatment of FFA, occurs in 10-25% of patients, more frequently by chloroquine than hydroxychloroquine (35 % vs 13%). 6 The lesions are typically blue-grey macules that enlarge and become confluent with variable distribution affecting: head, trunk, extremities and areas not exposed to the sun, including mucosal areas. Pigmentation onset ranges from four months to 22 years following the initiation of therapy, usually at high doses and the treatment consisted of discontinuing the antimalarial drug, which led to a gradual decrease in the hyperpigmentation within several months. 7 The histopathology consists of yellow to dark brown granules within macrophages and extracellularly in the dermis without inflammatory phase and damage to the dermo-epidermal junction.
Neither of the two entities have curative treatment. Photoprotection is essential in the LPP and other therapies include topical corticosteroids and tacrolimus, laser and oral retinoids, usually with poor results, although better response to treatment is observed in patients with a shorter duration (≤5 years) of disease and limited body area involvement. 8 In conclusion, we report another case of FFA with LPP. This is interesting because the patient is a Caucasian woman with a clear history of FFA preceding LPP, unlike most previously reported cases. Furthermore, this is the first case in which the LPP does not affect the face. In the presence of one of these entities, we believe it is important to consider this association, which is probably underdiagnosed. Early diagnosis of FFA is important to allow treatment with the intention of slowing or preventing progression, and although there are several therapeutic options for LPP, the results are usually unsatisfactory, and it seems to be better response in patients with shorter duration.q
